CJCU

Chem. J. Chinese Universities ›› 2013, Vol. 34 ›› Issue (1): 123.doi: 10.7503/cjcu20120330

• Biological Chemistry • Previous Articles     Next Articles

Inhibitory Effects of Phenylacetate on Proliferation and RNA Editing Deaminase ADAR1 Expression of Hepatocellular Carcinoma Cells SMMC-7721

WANG Yan1, FENG Zi-Xuan2, JIANG Tao1, FANG Xue-Dong3, CAO Hong3, ZHANG Yan3   

  1. 1. Department of General Surgery, China-Japan Union Hospital, Jilin University, Changchun 130033, China;
    2. College of Computer Science and Technology, Jilin University, Changchun 130012, China;
    3. Department of General Surgery, Second Hospital, Jilin University, Changchun 130021, China
  • Received:2012-04-10 Published:2012-12-31

PDF (PC)

Abstract:

To evaluate the inhibitory effects of phenylacetate(PA) on proliferation and RNA editing deaminase ADAR1 expression of hepatocellular carcinoma cells SMMC-7721, the inhibitory effects of different concentrations of PA(0.5, 1.0, 2.0 and 4.0 mmol/L) on hepatocellular carcinoma cells SMMC-7721 were detected by MTT and cell numeration methods. The cell percentages were tested by flow cytometry(FCM). The inhibitory effects of different doses of PA(0.5, 1.0 and 2.0 mmol/L) on the expression of RNA editing dea-minase(ADAR1 mRNA and protein) in SMMC-7721 cells were evaluated by RT-PCR and Western Blotting. With the increasing of concentrations of PA from 0.5 to 4.0 mmol/L and the prolonging time from 24 h to 72 h, the inhibitory rates of proliferation were significantly increased(P<0.05), but there was no significant difference between 2.0 and 4.0 mmol/L PA group for 72 h(P>0.05). With the increasing of concentrations of PA, the expression of RNA editing deaminase(ADAR1 mRNA and protein) was decreased(P<0.05). Further, we made down-regulation of the expression of ADAR1, the results showed that cancer cell proliferation was effectively inhibited. PA could inhibit the proliferation of hepatocellular carcinoma cells SMMC-7721 by the down-regulation of the expression of ADAR1 mRNA and protein in dependence on the time and doses.

Key words: Phenylacetate, Hepatocellular carcinoma, SMMC-7721, RNA editing deaminase, ADAR1

CLC Number: 

TrendMD: